Akarsu, MesutÖnem, SonerTuran, İlkerAdalı, GupseAkdoğan, MeralAkyıldız, MuratAladağ, MuratBalaban, YaseminDanış, NilayDayangaç, MuratGençdal, GencoGökcan, HaleSertesen, ElifGürakar, MerveHarputluoğlu, MuratKabaçam, GökhanKarademir, SedatKıyıcı, Muratİdilman, RamazanKarasu, Zeki2021-11-122021-11-122021Akarsu, M., Onem, S., Turan, I., Adali, G., Akdogan, M., Akyildiz, M., ... & Karasu, Z. (2021). Recommendations for Hepatitis B Immunoglobulin and Antiviral Prophylaxis Against Hepatitis B Recurrence After Liver Transplantation. The Turkish Journal of Gastroenterology: the Official Journal of Turkish Society of Gastroenterology, 32(9), 712-719.1300-49482148-5607https://doi.org/10.5152/tjg.2021.21608https://hdl.handle.net/20.500.12899/458he combination of hepatitis B immunoglobulin and potent nucleos(t)ide analogs after liver transplantation is considered as the standard of care for prophylaxis against hepatitis B virus recurrence. However, the recommended doses, route of administration, and duration of HBIG administration remain unclear. Moreover, hepatitis B immunoglobulin-free prophylaxis with potent nucleos(t)ide analogs has shown promising disease outcomes in preventing hepatitis B virus recurrence. The current recommendations, produced by the Turkish Association for the Study of the Liver, Acute Liver Failure and Liver Transplantation Special Interest Group, suggest a reduced need for hepatitis B immunoglobulin administration with effective long-term suppression of hepatitis B virus replication using potent nucleos(t) ide analogs after liver transplantation.eninfo:eu-repo/semantics/openAccessHepatitis BLiver transplantationRecurrenceArticle10.5152/tjg.2021.21608329712719346092992-s2.0-85117952374Q3WOS:000703346600001Q4